title: Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
abstract: Four patients (age 3-11 years at diagnosis) with relapsed acute promyelocytic leukemia (APL), 12-38 months from diagnosis, were treated with oral arsenic trioxide (As(2) O(3) ). One patient was treated with oral As(2) O(3) monotherapy and chemotherapy. Three patients failed initial oral or intravenous As(2) O(3) monotherapy were treated with oral As(2) O(3) plus ATRA followed by long-term oral maintenance (cumulative As(2) O(3) dose 280-2,100 mg). All patients achieved molecular remission, at a median follow up of 122 (10-132) months with no adverse effects. Oral As(2) O(3) , particularly in prolonged maintenance with oral ATRA may obviate the need of stem cell transplantation in relapsed pediatric APL.
authors: Department of Medicine, Queen Mary Hospital, Hong Kong, China. auwing@hotmail.com
authors: Wing Y
authors: WY
authors: Au
authors: Chi-Kong
authors: CK
authors: Li
authors: Vincent
authors: V
authors: Lee
authors: Hui Leung
authors: HL
authors: Yuen
authors: Jeffrey
authors: J
authors: Yau
authors: Godfrey C F
authors: GC
authors: Chan
authors: Shau-yin
authors: SY
authors: Ha
authors: Yok-lam
authors: YL
authors: Kwong
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000517:prevention & control*; D008297:Male; D010087:Oxides / Q000008:administration & dosage*; D012008:Recurrence; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide